Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.

New data reveals faster than ever hospital stroke response times, yet more to be done Key points The Australian Stroke Clinical Registry (AuSCR), run ...

Looking for help with today's New York Times Pips? We'll walk you through today's puzzle and help you match dominoes to tiles ...

Introduction Anaemia is highly prevalent among the indigenous population globally. Several interventions have been used to prevent and manage nutritional anaemia, including dietary measures, health ...